CoChat

GLP‐1: physiological effects and potential therapeutic applications

Aaboe, Kasper, Krarup, Thure, Madsbad, Sten, Holst, Jens Juul · 2008 · Diabetes, Obesity and Metabolism
Cited by 95

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Glucagon‐like peptide 1 (GLP‐1) is a gut‐derived incretin hormone with the potential to change diabetes. The physiological effects of GLP‐1 are multiple, and many seem to ameliorate the different conditions defining the diverse physiopathology seen in type 2 diabetes. In animal studies, GLP‐1 stimulates β‐cell proliferation and neogenesis and inhibits β‐cell apoptosis. In humans, GLP‐1 stimulates insulin secretion and inhibits glucagon and gastrointestinal secretions and motility. It enhances satiety and reduces food intake and has beneficial effects on cardiovascular function and endothelial dysfunction. Enhancing incretin action for therapeutic use includes GLP‐1 receptor agonists resistant to degradation (incretin mimetics) and dipeptidyl peptidase (DPP)‐4 inhibitors. In clinical trials with type 2 diabetic patients on various oral antidiabetic regimes, both treatment modalities efficaciously improve glycaemic control and β‐cell function. Whereas the incretin mimetics induce weight loss, the DPP‐4 inhibitors are considered weight neutral. In type 1 diabetes, treatment with GLP‐1 shows promising effects. However, several areas need clinical confirmation: the durability of the weight loss, the ability to preserve functional β‐cell mass and the applicability in other than type 2 diabetes. As such, long‐term studies and studies with cardiovascular end‐points are needed to confirm the true benefits of these new classes of antidiabetic drugs in the treatment of diabetes mellitus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00853.x

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 95

Metadata

Authors
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-10-14
Volume
10
Issue
11
Pages
994-1003
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2085770128
Cited by
95
References
40
FWCI
6.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP‐1: physiological effects and potential therapeutic applications. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00853.x
The paper
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008). GLP‐1: physiological effects and potential therapeutic applications. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00853.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.